Skip to content

FHN-PH: Held by 4 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›FIRST HORIZON CORP (FHN-PH)

FIRST HORIZON CORP

FHN-PH

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions.

Share

Score Holdings Short Interest Catalysts Insiders Research

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Signal Score

5.0/10

4 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 4 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

4 fund convergence

Deerfield Management

Driehaus Capital

Tang Capital Management

Eventide Asset ManagementHeld 5Q ↓

Position history (shares)

Deerfield Management

2Q

Driehaus Capital

6Q

Eventide Asset Management

6Q

AI Signal

Signal Note: FHN-PH (First Horizon Pharma)

Driehaus Capital's 21% position increase to $21.8M, coupled with convergence among four specialist biotech funds (Deerfield, Tang, Eventide), signals high conviction in the name. However, the note lacks specificity on near-term catalysts, cash runway, and the therapeutic rationale driving this multi-fund thesis—critical details needed to assess whether this reflects emerging data strength or valuation opportunism.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Aug 14, 2025

$1.3M

2 funds

Nov 14, 2025

$1.4M

2 funds

Feb 13, 2026

$216K

1 fund

Feb 17, 2026

$0

0 funds

-100% total institutional value over 15 quarters

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GEcoR1 Capital9.1%Apr 22, 2026

SC 13G/ADriehaus Capital4.8%Oct 13, 2022

SC 13G/ADriehaus Capital24.2%Oct 11, 2022

SC 13GDriehaus Capital5.2%Feb 14, 2022

Position Details

Deerfield ManagementEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

37 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

EHAB1 fund NVST1 fund MMSI1 fund ALNY1 fund DAWN1 fund DXCM1 fund BBNX1 fund IDYA1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: